AR070617A1 - PHARMACEUTICAL FORMULATION INCLUDING OXABISPIDINS / 236 - Google Patents

PHARMACEUTICAL FORMULATION INCLUDING OXABISPIDINS / 236

Info

Publication number
AR070617A1
AR070617A1 ARP090100600A ARP090100600A AR070617A1 AR 070617 A1 AR070617 A1 AR 070617A1 AR P090100600 A ARP090100600 A AR P090100600A AR P090100600 A ARP090100600 A AR P090100600A AR 070617 A1 AR070617 A1 AR 070617A1
Authority
AR
Argentina
Prior art keywords
modified release
oxabispidins
pharmaceutical
pharmaceutical formulation
pharmaceutical use
Prior art date
Application number
ARP090100600A
Other languages
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR070617A1 publication Critical patent/AR070617A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulacion de liberacion modificada que comprende oxabispidinas, como ingrediente activo, o una de sus sales aceptables para uso farmacéutico; y un portador o diluyente farmacéuticamente aceptable; para el uso en el tratamiento o la prevencion de arritmias cardiacas. Reivindicacion 1: Una formulacion farmacéutica de liberacion modificada en forma de un sistema unitario multiple, que comprende: I) miniesferas de liberacion inmediata que comprenden Compuesto A, o una de sus sales aceptables para uso farmacéutico; II miniesferas de liberacion modificada que comprenden compuesto A o una de sus sales aceptables para uso farmacéutico, revestidas con una membrana de difusion formada por material polimérico formador de película; en una relacion de las miniesferas de acuerdo con I) y II) de entre 10:90 y 90:10.A modified release formulation comprising oxabispidines, as an active ingredient, or one of its salts acceptable for pharmaceutical use; and a pharmaceutically acceptable carrier or diluent; for use in the treatment or prevention of cardiac arrhythmias. Claim 1: A pharmaceutical modified release formulation in the form of a multiple unit system, comprising: I) immediate release minifers comprising Compound A, or one of its salts acceptable for pharmaceutical use; II modified release minispheres comprising compound A or one of its salts acceptable for pharmaceutical use, coated with a diffusion membrane formed by polymeric film-forming material; in a relationship of the minispheres according to I) and II) between 10:90 and 90:10.

ARP090100600A 2008-02-22 2009-02-20 PHARMACEUTICAL FORMULATION INCLUDING OXABISPIDINS / 236 AR070617A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3064308P 2008-02-22 2008-02-22

Publications (1)

Publication Number Publication Date
AR070617A1 true AR070617A1 (en) 2010-04-21

Family

ID=40985767

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100600A AR070617A1 (en) 2008-02-22 2009-02-20 PHARMACEUTICAL FORMULATION INCLUDING OXABISPIDINS / 236

Country Status (5)

Country Link
AR (1) AR070617A1 (en)
PE (1) PE20091464A1 (en)
TW (1) TW200940110A (en)
UY (1) UY31669A1 (en)
WO (1) WO2009105023A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104586809A (en) * 2015-01-08 2015-05-06 浙江亚太药业股份有限公司 Esomeprazole magnesium enteric pill coated tablet and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2006135316A1 (en) * 2005-06-13 2006-12-21 Astrazeneca Ab New oxabispidine compounds for the treatment of cardiac arrhythmias
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
EP2018157A2 (en) * 2006-04-26 2009-01-28 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs

Also Published As

Publication number Publication date
TW200940110A (en) 2009-10-01
WO2009105023A1 (en) 2009-08-27
PE20091464A1 (en) 2009-10-24
UY31669A1 (en) 2009-09-30

Similar Documents

Publication Publication Date Title
CY1122575T1 (en) PHARMACEUTICAL FORMS OF DISTROMAT TABLET
UY30759A1 (en) CHEMICAL COMPOUNDS
CR11641A (en) UREA HETEROCICLICAL DERIVATIVES AND METHODS OF USE OF THE SAME-211
UY32158A (en) HETEROCICLIC DERIVATIVES AND METHODS OF USE OF THE SAME
UY32315A (en) PIPERIDINE COMPOUNDS AND USES OF THE SAME-596
CL2011003266A1 (en) Compounds derived from imidazolidin-2-one, with inhibitory activity of 17alpha-hydroxylase / lyase-c17,20; pharmaceutical composition comprising them; and use in the treatment of inflammation or cancer, among others.
UY31141A1 (en) PIPERIDINE COMPOUNDS AND ITS USES
BR112012008317A2 (en) sustained release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
CO6511251A2 (en) CHEMICAL COMPOUNDS
UY32816A (en) PHARMACEUTICAL FORMULATION BASED ON 1- [2- (2,1,3-BENZOTIADIAZOL-5-ILAMINO) -6 (2,6-DICLOROFENIL) -PIRIDO [2,3-D] PIRIMIDIN-7-IL] -3- TERT-BUTIL-URÉA
ECSP10010598A (en) CLEANING LIQUID METHODS AND COMPOSITIONS
CL2011000170A1 (en) Solid and stabilized pharmaceutical composition comprising a pharmaceutically active ingredient, titanium oxide and a plasticizer; procedure to stabilize the pharmaceutical composition during a light irradiation.
UY30544A1 (en) PIRROLO-PIPERIDINE COMPOUNDS AND PHARMACEUTICAL SALTS ACCEPTABLE OF THE SAME, MANUFACTURING PROCESSES, COMPOSITIONS AND APPLICATIONS
CO6491060A2 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
DOP2010000374A (en) UREA HETEROCICLICAL DERIVATIVES AND THEIR EMPLOYMENT METHODS
UY31860A (en) PIRIDINES OF TIAZOLO AS INHIBITORS OF THE GIRASA DNA
AR072685A1 (en) TOPICAL COMPOSITION FOR THE TREATMENT OF ACTINIC KERATOSIS
UY31864A (en) DERIVATIVES OF UREA HETERICÍCLICA AND METHODS OF USE OF THE SAME-332
UY32674A (en) UREA HETEROCICLICAL DERIVATIVES AND THEIR EMPLOYMENT METHODS
UY32316A (en) USEFUL PIPERIDINE DERIVATIVES IN THE TREATMENT OF BACTERIAL INFECTIONS
CL2011001829A1 (en) 3'-n-desmethyl-4 '' - o- (2-diethylaminoetanoyl) -6-o-methyl-9a-aza-9a-homoerythromycin a, its salts and crystalline forms 1, 2 and 3; Preparation process; use to treat inflammatory diseases; pharmaceutical composition; and composition which also comprises another active compound.
CO6382113A2 (en) CHEMICAL COMPOUNDS
CL2011000292A1 (en) Compounds derived from enfumafungin and its pharmaceutically acceptable salts, such as (1,3) -beta-d-glucan synthase inhibitors; pharmaceutical composition; and use to treat a fungal infection.
CR9839A (en) PHOTOSTABLE PHARMACEUTICAL COMPOSITION CONTAINING BRIVUDINE FOR THE TREATMENT OF HERPETIC CHERATITIS
AR070617A1 (en) PHARMACEUTICAL FORMULATION INCLUDING OXABISPIDINS / 236

Legal Events

Date Code Title Description
FB Suspension of granting procedure